The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
== Laboratory equipments and machines == Microscope – Scientific instrument for observing small objects Incubator – Device used to grow and maintain microbiological cultures or cell cultures Centrifuge – Device using centrifugal force to separate fluids Electrophoresis – Motion of charged particles in electric field Haematology – To count and identify blood cells at high speed and accuracy Spectrophotometer – Instrument to measure light intensity Glucometer – Medical device for determining the concentration of glucose in the blood Pipette – Liquid-transferring laboratory tool Beaker – Glass container used in laboratories Erlenmeyer flask – Laboratory flask with a flat bottom Petridish – Shallow dish used to hold cell cultures Hemocytometer – Medical device used to count cells Test tube – Glass or plastic laboratory glassware & Racks Hot air oven – Electrical device which uses dry heat to sterilize substances Refrigerator – Appliance for cold food storage Biochemistry analyzer – Medical laboratory instrumentPages displaying short descriptions of redirect targets Burette – Graduated glass tube with a tap at one end Water distillation – Water purified by condensing it from steamPages displaying short descriptions of redirect targets Analytical balance – Type of digital balance pH meter – Instrument measuring acidity or alkalinity of solutions
=== Brain === The brain parenchyma refers to the functional tissue in the brain that is made up of the two types of brain cell, neurons and glial cells. It is also known to contain collagen proteins. Damage or trauma to the brain parenchyma often results in a loss of cognitive ability or even death. Bleeding into the parenchyma is known as intraparenchymal hemorrhage.
== Side effects == Frequently (≥1% to <10%) reported adverse reactions with opipramol, especially at the beginning of the treatment, include fatigue, dry mouth, blocked nose, hypotension, and orthostatic dysregulation. Adverse reactions reported occasionally (≥0.1% to <1%) include dizziness, stupor, micturition disturbances, vigilance, accommodation disturbances, tremor, weight gain, thirst, allergic skin reactions (rash, urticaria), abnormal ejaculation, erectile impotence, constipation, transient increases in liver enzymes, tachycardia, and palpitations. Rarely (≥0.01% to <0.1%) reported adverse reactions include excitation, headache, paresthesia especially in elderly patients, restlessness, sweating, sleep disturbances, edema, galactorrhea, urine blockage, nausea and vomiting, fever, collapse conditions, stimulation conducting disturbances, intensification of present heart insufficiency, blood profile changes particularly leukopenia, confusion, delirium, stomach complaints, taste disturbance, and paralytic ileus especially with sudden discontinuation of a longer-term high-dose therapy. Very rarely (<0.01%) reported adverse reactions include seizures, motor disorders (akathisia, dyskinesia, ataxia), polyneuropathy, glaucoma, anxiety, hair loss, agranulocytosis, severe liver dysfunction after long-term treatment, jaundice, and chronic liver damage.
This region is as extensive as the Amazon basin but has a very different climate as it lies farther south at a higher altitude. In the interior northeast, seasonal rainfall is even more extreme. South of Bahia, near the coasts, and more southerly most of the state of São Paulo, the distribution of rainfall changes, with rain falling throughout the year. The south enjoys subtropical conditions, with cool winters and average annual temperatures not exceeding 18 °C (64.4 °F); winter frosts and snowfall are not rare in the highest areas. The semiarid climatic region generally receives less than 800 millimeters (31.5 in) of rain, most of which generally falls in a period of three to five months of the year and occasionally less than this, creating long periods of drought. Brazil's 1877–78 Grande Seca (Great Drought), the worst in Brazil's history, caused approximately half a million deaths. A similarly devastating drought occurred in 1915. In 2024, for the first time, "a drought has covered all the way from the North to the country's Southeast". It is the strongest drought in Brazil since the beginning of measurement in the 1950s, covering almost 60% of the country's territory. The drought is linked to deforestation and climate change.
Sources: en.wikipedia.org
=== Biosynthesis === Biosynthesis takes place in bacteria, fungi and plants, but not animals. The biosynthetic precursors to riboflavin are ribulose 5-phosphate and guanosine triphosphate. The former is converted to L-3,4-dihydroxy-2-butanone-4-phosphate. Guanosine is degraded to 4-hydroxy-2,4,5-triaminopyrimidine, which is transformed into 5-amino-6-(D-ribitylamino)uracil. These two compounds are then the substrates for the penultimate step in the pathway, catalysed by the enzyme lumazine synthase in reaction EC 2.5.1.78.
Chemistry Tree: Paul J. Flory Details Paul Flory on Nobelprize.org A short autobiography of Paul Flory Nobel lecture by Paul Flory Mangravite, Andrew (2001). "Finding Aid to the Paul J. Flory papers, 1931–1985 bulk 1950–1978". Science History Institute. Retrieved March 27, 2018. Click on 'Paul J. Flory papers finding aid' for full finding aid. Paul J. Flory papers at the Hoover Institution Archives National Academy of Sciences Biographical Memoir
These isoenzymes include MM, MB, and BB, which all carry out the same function given different amino acid sequences. The functions of these isoenzymes are to convert creatine, using ATP, into phosphocreatine expelling ADP. Mini columns were filled with DEAE-Sephadex A-50 and further eluted with tris- buffer sodium chloride at various concentrations (each concentration was chosen advantageously to manipulate elution). Human tissue extract was inserted in columns for separation. All fractions were analyzed to see total CK activity and it was found that each source of CK isoenzymes had characteristic isoenzymes found within. Firstly, CK- MM was eluted, then CK-MB, followed by CK-BB. Therefore, the isoenzymes found in each sample could be used to identify the source, as they were tissue specific. Using the information from results, correlation could be made about the diagnosis of patients and the kind of CK isoenzymes found in most abundant activity. From the finding, about 35 out of 71 patients studied suffered from heart attack (myocardial infarction) also contained an abundant amount of the CK-MM and CK-MB isoenzymes. Findings further show that many other diagnosis including renal failure, cerebrovascular disease, and pulmonary disease were only found to have the CK-MM isoenzyme and no other isoenzyme. The results from this study indicate correlations between various diseases and the CK isoenzymes found which confirms previous test results using various techniques.
Sources: en.wikipedia.org
== History == The Human Protein Atlas program was started in 2003 and funded by the non-profit organization Knut and Alice Wallenberg Foundation (KAW). The main site of the project is the Royal Institute of Technology (KTH), School of Engineering Sciences in Chemistry, Biotechnology and Health (Stockholm, Sweden). Additionally, the project involves research groups at Uppsala University, Karolinska Institutet, Chalmers University of Technology and Lund University, as well as several present and past international collaborations initiated with research groups in Europe, the United States, South Korea, China, and India. Professor Mathias Uhlén is the director of the program. The research underpinning the start of the exploration of the whole human proteome in the Human Protein Atlas program was carried out in the late 1990s and early 2000s. A pilot study employing an affinity proteomics strategy using affinity-purified antibodies raised against recombinant human protein fragments was carried out for a chromosome-wide protein profiling of chromosome 21. Other projects were also carried out to establish processes for parallel and automated affinity purification of mono-specific antibodies and their validation.
The bill passed by a bipartisan vote and prohibits pharmacy benefit managers from sending customers to pharmacies they have a financial interest in and from charging health insurance plans a higher price for a drug than what the pharmacy benefit managers pay the pharmacy.
=== Biophysical carbon dioxide-concentrating mechanisms === This type of carbon dioxide-concentrating mechanism (CCM) relies on a contained compartment within the cell into which CO2 is shuttled, and where RuBisCO is highly expressed. In many species, biophysical CCMs are only induced under low carbon dioxide concentrations. Biophysical CCMs are more evolutionary ancient than biochemical CCMs. There is some debate as to when biophysical CCMs first evolved, but it is likely to have been during a period of low carbon dioxide, after the Great Oxygenation Event (2.4 billion years ago). Low CO2 periods occurred around 750, 650, and 320–270 million years ago.
== Structure == Basophils contain large cytoplasmic granules which obscure the cell nucleus under the microscope when stained. However, when unstained, the nucleus is visible and it usually has two lobes. The mast cell, another granulocyte, is similar in appearance and function. Both cell types store histamine, a chemical that is secreted by the cells when stimulated. However, they arise from different branches of hematopoiesis, and mast cells usually do not circulate in the blood stream, but instead are located in connective tissue. Like all circulating granulocytes, basophils can be recruited out of the blood into a tissue when needed.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.